What is CVE-2026-76411?
A vulnerability in the phishcheck functionality of ClamAV could allow an unauthenticated, remote attacker to cause a DoS condition on an affected device. This vulnerability is due to improper allocation of memory during processing of URLs. An attacker could exploit this vulnerability by sending a URL to be processed by the software. A successful exploit could allow the attacker to cause the ClamAV scanning process to terminate, resulting in a DoS condition on the affected software.
The record classifies CVE-2026-76411 under weakness class CWE-120. Its CVSS v3 base vector states that the flaw is reachable remotely over the network, needs no prior authentication, needs no user interaction, and has high impact on availability. 1 affected-product entry is recorded, across 1 vendor, listed below. The identifier was first published 3 days ago.
Severity and exploitation probability
- CVSS v3.1 base score
- 7.5 — HIGH
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H - EPSS (FIRST)
- 0.5% probability of exploitation in the next 30 days, higher than 48.9% of all scored CVEs
- CISA KEV
- Not listed in the CISA Known Exploited Vulnerabilities catalog
- Threadlinqs priority
- 5.7/10 — a Threadlinqs composite of the CVSS base score, the EPSS percentile and public exploit availability
- Published
- 2026-11-18
Is CVE-2026-76411 being exploited?
It currently carries a trending score of 5 in the Threadlinqs vulnerability feed.
Affected products and versions
- Cisco: Secure Endpoint
How to fix CVE-2026-76411
No vendor patch reference has been recorded for CVE-2026-76411 in the tracked sources. Follow the references below for a fix, and treat the products listed above as exposed until the vendor states otherwise.
Threat activity tracking CVE-2026-76411
1 tracked threat in the Threadlinqs corpus references CVE-2026-76411, either in the campaign’s CVE list or as an indicator on the campaign record.
Sources
Enriched from CVE.org, NVD, FIRST EPSS. This product uses the NVD API but is not endorsed or certified by the NVD.